Loading...
NPI 1518406636 · Dallas, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Gentech Laboratories LLC is a clinical medical laboratory provider located in Dallas, Texas. This profile covers 5 Medicare and 18 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Gentech Laboratories LLC |
| Address | 4403 N Beltwood Pkwy Ste 100 |
| City | Dallas |
| State | TX |
| ZIP | 75244 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 22, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $91.8M |
| Medicare | $3.3M |
Provider profile and tenure: GENTECH LABORATORIES LLC is a Clinical Medical Laboratory based in DALLAS, TX with an NPI enumerated 2017-02-22 (~9 years ago). The billing mix on file shows active participation in both Medicare and Medicaid, with extensive volume in molecular and antigen testing codes tied to respiratory pathogens.
Payer mix and scale: Medicaid activity ($91.8M lifetime revenue) dwarfs Medicare activity ($3.3M lifetime revenue), indicating that this entity operates at scale primarily within the Medicaid market rather than as a balanced dual-payor laboratory. In practical terms, Medicaid is the dominant revenue source by a large margin.
Business/service-line implication — test menu and operations: The top codes billed (87636, 87637, 87426, U0004 and G2023) are all SARS-CoV-2/respiratory pathogen molecular or antigen tests and accompanying specimen collection, which signals a high-throughput infectious disease testing operation focused on multiplex respiratory panels and COVID-19 diagnostics. The presence of large claim counts such as 20K Medicare claims for 87636 and 286.5K Medicaid claims for 87637 implies centralized laboratory processing and sizable specimen intake/collection workflows.
Medicare revenue concentration and leading Medicare codes: GENTECH’s Medicare revenue is highly concentrated — the top three Medicare codes account for 97.3% of its Medicare revenue. The provider’s Medicare billing is led by 87636 ($2.7M revenue, 20K claims; 82.5% of this provider's total Medicare revenue), which ranks #2 of 2192 nationally (100th percentile; extreme outlier), followed by 87426 ($410.2K, 11.7K claims) ranking #2 of 17750 (100th percentile; extreme outlier) and 87637 ($75.9K, 584 claims) ranking #51 of 1141 (96th percentile; typical).
Medicaid revenue concentration and in-state dominance: The top three Medicaid codes account for 91.8% of this provider’s Medicaid revenue, showing similar concentration on a small set of respiratory testing services. Notably, 87637 ($36.4M, 286.5K claims) and 87636 ($36M, 285.6K claims) each represent roughly 39% of Medicaid revenue and both rank #1 in-state (100th percentile; extreme outlier), while 87426 contributes $11.8M (12.8% of Medicaid revenue) and ranks #2 in-state (100th percentile; extreme outlier).
Competitive standing: For its leading test types GENTECH is a dominant player — nationally it is an outlier on Medicare for 87636 and 87426 (both rank #2 and are described as extreme outliers), and statewide it is the top-ranked provider for the two largest Medicaid drivers (87637 and 87636 at #1 in-state). These rank/percentile positions indicate market-leading volume for respiratory molecular testing versus peers.
Operational signals from ancillary codes and claim volumes: High counts for specimen-collection and high-throughput lab codes (e.g., Medicaid G2023 with 51.9K claims, $934.4K revenue, rank #2 in-state; U0004 with 108.8K Medicaid claims, $6.3M revenue, rank #2 in-state) suggest GENTECH manages both testing throughput and specimen logistics at scale. The combination of large claim volumes and top-state rankings is consistent with centralized processing capacity and significant testing throughput contracts or client relationships.
Concentration implications: The provider’s revenue is heavily concentrated in COVID-19 and multiplex respiratory testing codes (top 3 Medicare = 97.3% of Medicare revenue; top 3 Medicaid = 91.8% of Medicaid revenue). This concentrated service mix makes the organization highly exposed to shifts in demand or reimbursement for these specific test categories, while also explaining its unusually large rankings where demand remained high.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 19,950 | $140 | $2.7M |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 11,720 | $40 | $410.2K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 580 | $130 | $75.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,790 | $20 | $64.1K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 310 | $70 | $23K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
18 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 286,500 | $130 | $36.4M |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 285,590 | $130 | $36M |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 367,790 | $30 | $11.8M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 108,760 | $60 | $6.3M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 51,910 | $20 | $934.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 29,850 | $10 | $268.7K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 890 | $40 | $32K |
| 86328 | The lab analyst performs a single–step immunoassay to qualitatively or semiquantitatively evaluate the patient’s specimen for antibodies to the severe acute respiratory syndrome coronavirus 2… | 10 | $20 | $270 |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 340 | $0 | $0 |
| 87471 | The lab analyst performs a test for Bartonella henselae and Bartonella quintana using amplified nucleic acid probe technique. | 50 | $0 | $0 |
Showing 1–10 of 18
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
18 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 1 | 120 | 340 | $120 | $422K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 1 | 160 | 200 | $110 | $323.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2 | 100 | 470 | $50 | $319.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 56 | 110 | 360 | $40 | $174.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 12 | 260 | 640 | $20 | $137.2K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 2 | 1,350 | 320 | $30 | $101.2K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 121 | 170 | 440 | $20 | $93.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 247 | 850 | 260 | $40 | $77.5K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 342 | 420 | 340 | $20 | $73.4K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 27 | 50 | 380 | $20 | $63.4K |
Showing 1–10 of 18
Other providers in the same ZIP code as Gentech Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Therapy Management Services, LLC. | TX | Home Health Agency | $0 | $76.2M |
| Awh Financial Services LLC | TX | Supports Brokerage Agency | $0 | $34M |
| Signify Health, LLC | TX | General Practice Physician | $0 | $12.7M |
| Signify Health Medical Associates, PLLC | TX | General Practice Physician | $0 | $11.3M |
| Concepta Labs, LLC | TX | Clinical Medical Laboratory | $2.4M | $47.3K |
| Dedrick Ahmed | TX | Optometrist | $260.4K | $0 |
| Daniel Shropshire | TX | Optometrist | $223.7K | $1.7K |
| Carlos Marquez De La Plata | TX | Clinical Neuropsychologist | $143.2K | $0 |
| Omali Diagnostics LLC | TX | Clinical Medical Laboratory | $101.6K | $1.7K |
| Christina Roberts | TX | Family Nurse Practitioner | $67.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.